Catalyst Dossier · compiled by Celia 🧫

Vertex Pharmaceuticals Incorporated (VRTX)

Pharmaceutical Preparations · market cap $114.6B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-03

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vertex Pharmaceuticals (VRTX) is a large-cap biopharma with a $118B market cap, anchored by a dominant cystic fibrosis franchise spanning multiple approved and late-stage CFTR modulator combinations. The company generated $12B in revenue and $3.95B in net income in 2025, and holds $5.5B in net cash, while extending its pipeline into pain, kidney disease, Type 1 diabetes, and sickle cell disease.

The catalyst path

2026-08-03Earningsimp 5/10
2026-09-17 (est.)Phase 3 · Biological/Vaccineimp 9/10
2026-10-30 (est.)Phase 3 · VX-121/TEZ/D-IVAimp 9/10
2026-12-23 (est.)Phase 2 · IVAimp 7/10
2026-12-30 (est.)Phase 2 · Inaxaplinimp 7/10
2027-01-25 (est.)Phase 3 · Suzetrigineimp 9/10
2027-01-27 (est.)PDUFA · Povetaciceptimp 8/10
2027-02-02 (est.)Phase 2 · VX-670imp 7/10

Pipeline

Asset	Phase	Indication
VX-548	Phase 2	Acute Pain
Lumacaftor	Phase 3	Cystic Fibrosis
VX-661	Phase 2	Cystic Fibrosis
Cethrin	Phase 2	Spinal Cord Injury
ELX/TEZ/IVA	Phase 3	Cystic Fibrosis
VX-661 plus ivacaftor combination	Phase 3	Cystic Fibrosis
IVA	Phase 3	Cystic Fibrosis
VX-150	Phase 2	Osteoarthritis
Tezacaftor/Ivacaftor	Phase 3	Cystic Fibrosis
LUM/IVA	Phase 3	Cystic Fibrosis
Ivacaftor	Phase 3	Cystic Fibrosis
Ivacaftor 25 mg/75 mg	Phase 2	Cystic Fibrosis
VX-702	Phase 2	Rheumatoid Arthritis
VX-445/TEZ/IVA	Phase 3	Cystic Fibrosis
Inaxaplin	Phase 2	Proteinuric Kidney Disease
VX-880	Phase 3	Type 1 Diabetes
VX-121	Phase 2	Cystic Fibrosis
VX-787	Phase 2	Influenza Virus
ribavirin	Phase 3	Hepatitis C
VX-222	Phase 2	Chronic Hepatitis C Virus

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.